United Kingdom: Accord Healthcare Limited v. Medac Gesellschaft Für Klinische Spezialpräparate MBH, High Court of Justice of England and Wales, Chancery Division, Patents Court, HP-2014-000011, 13 January 2016
The Patents Court (Birss J) held that medac’s patent EP (UK) 2 046 332 relating to the use of a formulation of methotrexate at a concentration of about 50 mg/ml for the treatment of individuals with inflammatory autoimmune diseases such as rheumatoid arthritis (RA) by subcutaneous injection, was obvious over one of the prior art…